Neoleukin Therapeutics Inc. (NASDAQ: NLTX) open the trading on March 16, 2023, with great promise as it jumped 12.69% to $0.70. During the day, the stock rose to $0.70 and sunk to $0.63 before settling in for the price of $0.62 at the close. Taking a more long-term approach, NLTX posted a 52-week range of $0.38-$2.32.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Meanwhile, its Annual Earning per share during the time was 10.90%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -71.70%. This publicly-traded company’s shares outstanding now amounts to $55.25 million, simultaneously with a float of $33.47 million. The organization now has a market capitalization sitting at $34.05 million. At the time of writing, stock’s 50-day Moving Average stood at $0.5711, while the 200-day Moving Average is $0.7452.
Neoleukin Therapeutics Inc. (NLTX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Drug Manufacturers – Specialty & Generic industry. Neoleukin Therapeutics Inc.’s current insider ownership accounts for 21.49%, in contrast to 45.00% institutional ownership. According to the most recent insider trade that took place on Feb 02, this organization’s Chief Medical Officer sold 14,380 shares at the rate of 0.60, making the entire transaction reach 8,588 in total value, affecting insider ownership by 31,082. Preceding that transaction, on Feb 02, Company’s Principal Accounting Officer sold 3,316 for 0.60, making the whole transaction’s value amount to 1,980. This particular insider is now the holder of 15,960 in total.
Neoleukin Therapeutics Inc. (NLTX) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 9/29/2022 suggests? It has posted -$0.24 earnings per share (EPS) beating the forecaster’s viewpoint (set at -$0.3) by $0.06. This company achieved a return on equity of -36.33. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
Neoleukin Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -71.70% and is forecasted to reach -0.64 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 25.10% through the next 5 years, which can be compared against the 10.90% growth it accomplished over the previous five years trading on the market.
Neoleukin Therapeutics Inc. (NASDAQ: NLTX) Trading Performance Indicators
Let’s observe the current performance indicators for Neoleukin Therapeutics Inc. (NLTX). It’s Quick Ratio in the last reported quarter now stands at 10.60. The Stock has managed to achieve an average true range (ATR) of 0.06.
In the same vein, NLTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.07, a figure that is expected to reach -0.21 in the next quarter, and analysts are predicting that it will be -0.64 at the market close of one year from today.
Technical Analysis of Neoleukin Therapeutics Inc. (NLTX)
[Neoleukin Therapeutics Inc., NLTX] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 58.03% While, its Average True Range was 0.0689.
Raw Stochastic average of Neoleukin Therapeutics Inc. (NLTX) in the period of the previous 100 days is set at 84.19%, which indicates a major rise in contrast to 77.44% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 146.85% that was higher than 93.24% volatility it exhibited in the past 100-days period.